UK Coalition government Spending Review protects science and health research budgets

21 October 2010

In yesterday’s announcement by the UK’s Coalitions government of massive public spending cuts, the Department for Business, Innovation and Skills (BIS) will reduce its resource budget by 25 per cent. Taking into account anticipated receipts, the cut to capital spending by 2014-15 will be 44 per cent.

However, says the BIS, the government will ensure the UK remains a world leader in science and research. To do this it will continue support for the highest value scientific research, maintaining the science budget in cash terms over the Comprehensive Spending Review period with resource spending of £4.6 billion ($7.36 billion) a year by 2014-15.

A ring fence will be maintained by the Department for Business to ensure continuity of investment in Science and Research. Key capital projects going ahead include £220 million in funding to ensure that the UK Centre for Medical Research Innovation goes ahead as planned.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology